Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a promising therapeutic class for neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD). Originally developed for type 2 diabetes, these drugs have shown neuroprotective, anti-inflammatory, and anti-aggregating properties in preclinical models.
GLP-1 receptor activation triggers multiple downstream pathways relevant to neurodegeneration:
- cAMP/PKA/CREB pathway: Promotes neuronal survival and gene expression
- PI3K/Akt signaling: Inhibits apoptosis and enhances cell viability
- ERK1/2 activation: Supports neuroplasticity and memory formation
- mTOR modulation: Regulates autophagy and protein homeostasis
Preclinical evidence suggests GLP-1 agonists may address multiple AD hallmarks:
- Reduced amyloid-beta production and aggregation
- Decreased tau phosphorylation
- Attenuated neuroinflammation
- Enhanced synaptic plasticity
- Mitochondrial protection
In PD models, GLP-1 agonists have shown:
- Protection against dopaminergic neuron loss
- Reduced alpha-synuclein aggregation
- Improved mitochondrial function
- Anti-inflammatory effects in the substantia nigra
| Drug/Program |
Target |
Company |
Development Stage |
Indication |
| Liraglutide (Victoza) |
GLP-1R |
Novo Nordisk |
Phase II/III (repurposed) |
AD, PD |
| Exenatide (Bydureon) |
GLP-1R |
AstraZeneca |
Phase II (repurposed) |
PD |
| Dulaglutide (Trulicity) |
GLP-1R |
Eli Lilly |
Phase II (repurposed) |
AD |
| Semaglutide (Ozempic/Wegovy) |
GLP-1R |
Novo Nordisk |
Phase III (repurposed) |
AD |
| Tirzepatide (Mounjaro) |
GLP-1R/GIPR |
Eli Lilly |
Phase II (repurposed) |
AD |
| Ly3502970 (Orforglipron) |
GLP-1R (oral) |
Eli Lilly |
Phase II |
AD |
| Ecnoglutide |
GLP-1R |
None |
Phase I (preclinical) |
PD |
Several trials are investigating GLP-1 agonists in AD:
- NCT04777409: Liraglutide in Early AD — Phase II, completed 2024
- NCT05360095: Semaglutide in Early AD — Phase III, recruiting
- NCT05474456: Tirzepatide in MCI due to AD — Phase II, recruiting
- NCT05668069: Dulaglutide in Early AD — Phase II, active
PD trials have shown promising signals:
- NCT01971242: Exenatide in PD — Phase II, completed (positive motor outcomes)
- NCT03439930: Exenatide in PD — Phase III, ongoing
- NCT04564898: Liraglutide in PD — Phase II, completed
- NCT05711208: Semaglutide in PD — Phase II, recruiting
GLP-1 therapeutics for neurodegeneration have benefited from:
- Repurposing advantage: Existing safety data enables faster development
- Large pharma commitment: Novo Nordisk and Eli Lilly have active programs
- Growing pipeline: 15+ compounds in various development stages
The neurodegenerative GLP-1 market represents a significant opportunity:
- Addressable population: ~6 million AD patients, ~1 million PD patients in US
- Premium pricing potential for disease-modifying therapies
- Combination therapy opportunities with other mechanisms
- Novo Nordisk: Lead in GLP-1 neurodegeneration (liraglutide, semaglutide)
- Eli Lilly: Tirzepatide (dual GLP-1/GIP), orforglipron (oral)
- AstraZeneca: Exenatide program in PD
- Pfizer: Danuglipron (oral GLP-1) in development
- University of Cambridge: Prof. Christian Hölscher (pioneering GLP-1 research)
- University of Virginia: Dr. Jeffrey Burns (PD clinical trials)
- Karolinska Institute: GLP-1 and neuroinflammation research
- Combination approaches: GLP-1 with anti-amyloid, anti-tau, or autophagy enhancers
- Biomarker development: Patient selection and response markers
- Genetic subtypes: Response in APOE4 carriers, LRRK2 carriers
- Disease prevention: GLP-1 in prodromal populations
- Head-to-head comparisons: Different GLP-1 agonists in same trial
- BBB penetration: Variable CNS exposure across compounds
- Dosing: CNS-effective doses may differ from metabolic dosing
- GI side effects: Tolerability may limit long-term use
- Immunogenicity: Antibody formation with some compounds
- Dual/triple agonists: GIP/GLP-1 combinations (tirzepatide)
- Brain-penetrant analogs: Next-generation GLP-1 compounds
- Early intervention: Trials in prodromal AD and REM sleep behavior disorder (PD)
- Biomarker integration: Tau PET, CSF markers for patient selection
Based on gap analysis, priority areas for investment include:
- Oral GLP-1 compounds for CNS indications
- Biomarker development for patient stratification
- Combination therapy trials
- Prevention studies in at-risk populations